The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis.

OBJECTIVE To analyze the factors associated with survival in patients with pulmonary and extrapulmonary tuberculosis in New York City. DESIGN Observational study of a citywide cohort of tuberculosis cases. SETTING New York City, April 1991, before the strengthening of its control program. PATIENTS All 229 newly diagnosed cases of tuberculosis documented by culture in April 1991. Most patients (74%) were male, and the median age was 37 years (range, 1-89 years). In all, 89% belonged to minority groups. Human immunodeficiency virus (HIV) infection was present in 50% and multidrug resistance in 7% of the cases. Twenty-one patients (9%) were not treated. MAIN OUTCOME MEASURES Follow-up information was collected through the New York City tuberculosis registry; death from any cause was verified through the National Death Index. RESULTS Cumulative all-cause mortality by October 1994 was 44%; the median survival for those who died was 6.3 months (range, 0 days to 3 years). The most important baseline predictors of mortality, adjusted for baseline clinical and demographic factors, were acquired immunodeficiency syndrome (AIDS) (91% vs 11% in HIV-seronegative patients; Cox relative risk [RR], 7.8; 95% confidence interval [CI], 2.1-29.1), multidrug resistance (87% vs 39% in pansensitive cases; adjusted RR, 5.8; 95% CI, 2.3-14.5), and lack of treatment (81% vs 40%; adjusted RR, 3.1; 95% CI, 1.0-9.7). Also, 11 of 13 HIV-infected patients who started treatment after a 1-month delay died. Among 173 patients surviving the recommended treatment period, those who completed therapy (66%) had a lower subsequent mortality (20% vs 37%; RR, 0.5; 95% CI, 0.3-0.9). CONCLUSIONS Mortality from tuberculosis was high, even among patients without multidrug resistance who were not known to be infected with HIV. Most HIV-seropositive patients with delayed therapy died. Multidrug resistance predicted higher mortality, and treatment completion was associated with improved subsequent patient survival.

[1]  K. Sepkowitz,et al.  Multidrug-resistant tuberculosis in patients without HIV infection. , 1995, The New England journal of medicine.

[2]  R. Chaisson,et al.  Eleven years of community-based directly observed therapy for tuberculosis. , 1995, JAMA.

[3]  T. Frieden,et al.  Tuberculosis in New York City--turning the tide. , 1995, The New England journal of medicine.

[4]  P. Piot,et al.  Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. , 1995, The New England journal of medicine.

[5]  K. D. de Cock,et al.  Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire , 1995, The Lancet.

[6]  D E Snider,et al.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. , 1995, JAMA.

[7]  D. Snider,et al.  Epidemiology of tuberculosis in the United States, 1985 through 1992. , 1994, JAMA.

[8]  R. Chaisson,et al.  Effectiveness of supervised, intermittent therapy for tuberculosis in HIV‐infected patients , 1994, AIDS.

[9]  E. Drucker,et al.  Childhood tuberculosis in the Bronx, New York , 1994, The Lancet.

[10]  P. Graf.  Framework for effective tuberculosis control , 1994 .

[11]  D. Snider,et al.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. , 1994, American journal of respiratory and critical care medicine.

[12]  D. Snider,et al.  Nationwide survey of drug-resistant tuberculosis in the United States. , 1994, JAMA.

[13]  L. Sacks,et al.  Delayed diagnosis of pulmonary tuberculosis in city hospitals. , 1994, Archives of internal medicine.

[14]  W. Rom,et al.  The third epidemic--multidrug-resistant tuberculosis. , 1994, Chest.

[15]  Susan Z. Barrows,et al.  Tuberculosis in the 1990s , 1993, Annals of Internal Medicine.

[16]  T. Coté,et al.  Trends in death with tuberculosis during the AIDS era. , 1993, JAMA.

[17]  M. Iseman,et al.  Directly observed treatment of tuberculosis. We can't afford not to try it. , 1993, The New England journal of medicine.

[18]  L. Ackerson,et al.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.

[19]  T. Frieden,et al.  The emergence of drug-resistant tuberculosis in New York City. , 1993, The New England journal of medicine.

[20]  Marija J. Norusis,et al.  SPSS for Windows, Advanced Statistics, release 6.0 , 1993 .

[21]  T. Singh,et al.  Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition. , 1992, Archives of internal medicine.

[22]  S. Oldham,et al.  Clinical Presentation and Outcome of Patients with HIV Infection and Tuberculosis Caused by Multiple-Drug-resistant Bacilli , 1992, Annals of Internal Medicine.

[23]  D. Snider,et al.  Tuberculosis morbidity in the United States: final data, 1990. , 1991, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[24]  K. Brudney,et al.  Resurgent Tuberculosis in New York City: Human Immunodeficiency Virus, Homelessness, and the Decline of Tuberculosis Control Programs , 1991, The American review of respiratory disease.

[25]  D. Snider,et al.  Tuberculosis diagnosed at death in the United States. , 1991, Chest.

[26]  R. Chaisson,et al.  Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[27]  M. Mendelson,et al.  Resurgence of tuberculosis: relationship to HIV infection and implications for infection control. , 1990, The Mount Sinai journal of medicine, New York.

[28]  M. Taniguchi,et al.  [A study of causes of death among patients with active pulmonary tuberculosis from the standpoint of host factors]. , 1990, Kekkaku : [Tuberculosis].

[29]  D. Snider,et al.  The epidemiology of tuberculosis in the United States. Implications for diagnosis and treatment. , 1989, Clinics in chest medicine.

[30]  R. Chaisson,et al.  Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. , 1987, The American review of respiratory disease.

[31]  D. Mitchison,et al.  Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[32]  W. Willett,et al.  Test of the National Death Index. , 1984, American journal of epidemiology.